Executive Management | Harrow, Inc.

Mark L. Baum is the founder, Chairman of the Board, and Chief Executive Officer of Harrow. Mr. Baum is a founder and former board member of Eton Pharmaceuticals (Nasdaq: ETON) and Surface Ophthalmics, as well as a founder and the current Chairman of the Board of Melt Pharmaceuticals. From 2014-2017, Mr. Baum was a senior advisor to Curology.com. Before Harrow, as the founder of TBLF, LLC, a private investment fund manager, Mr. Baum made more than 200 investments in, and provided advisory and board service to, more than 40 private and public companies. In 1999, Mr. Baum founded YesRx, an HIV-focused pharmacy business. Mr. Baum actively advocates for patient and physician pharmaceutical accessibility issues, including being featured in Op-Ed contributions for the Wall Street Journal and appearances on national and international media outlets and other forums. Mr. Baum was named by Ernst & Young LLP as the 2017 Entrepreneur of the Year™ in the life sciences category for the San Diego region. Mr. Baum serves on the board of the Ophthalmology Foundation, which works with eye care professionals and professional societies to enhance and provide ophthalmic education, focusing on low-resource and underserved countries. Mr. Baum is a graduate, cum laude, of The University of Texas at Arlington and a 1997 graduate of California Western School of Law.

Andrew R. Boll, a founding employee of Harrow, serves as Chief Financial Officer and Corporate Secretary, overseeing the Company’s financial, market access and administrative operations. Mr. Boll also co‑founded Eton Pharmaceuticals (Nasdaq: ETON), Melt Pharmaceuticals, Surface Ophthalmics, and ImprimisRx. Before joining Harrow, he managed accounting, financial analysis, and reporting for an investment company from 2007 to 2011, and he was also heavily involved with the financial operations of a number of the fund’s portfolio companies (public and private). Prior to 2007, Mr. Boll held various accounting roles at Welsh Companies, a commercial real estate company, its fund and its other subsidiaries. Mr. Boll is a CFA® charterholder, a Certified Management Accountant (CMA®), and graduated summa cum laude with a Bachelor of Science in Corporate and Public Finance.

KJ Barratt has served as Chief Talent Officer of Harrow since July 2022. Ms. Barratt is an accomplished operations leader with a 20-year record of driving higher profitability through a participative-management style of leadership that incorporates Six Sigma thinking, principles, and tools to achieve sustainable changes in process design, speed, cost, and quality. Prior to joining Harrow, Ms. Barratt worked for over six years with Novatech, a nationwide business technology provider, most recently as Chief Human Resources Officer responsible for all aspects of human resources, payroll and compensation, employee benefits and career mapping, recruitment and talent acquisition, employee law and policy compliance, company culture and community involvement. Prior to joining Novatech, she served in various leadership roles including Executive Vice President of Operations for Skyway Studies, Chief Resource Officer for Fort Campbell Federal Credit Union, and Manager, Learning and Development for Ingram Content Group. Ms. Barratt has a Master of Education degree in Human Resources Development from Vanderbilt University as well as a Master of Science in Leadership, Employment Law from Grand Canyon University.

Brett A. Burrell has served as Harrow’s Vice President of Legal and Compliance since October 2023. Mr. Burrell has over 25 years of experience as a healthcare attorney and has led compliance program efforts for companies in several industry segments including pharmaceuticals, hospitals, behavioral health, and toxicology. He has advised on a wide range of regulatory issues, including privacy, healthcare reimbursement, and pharmaceutical sales and marketing matters. Mr. Burrell obtained his law degree from the University of Memphis, his MBA from the University of Mississippi, and earned his Bachelor of Science degree, cum laude, in Accounting from Tennessee Technological University.

John P. Saharek is President and Chief Executive Officer of Harrow’s ImprimisRx Division. Mr. Saharek has over 30 years of broad experience developing and commercializing pharmaceutical, biologic, surgical device and diagnostic product portfolios. His results-oriented record of achievement includes designing and executing strategic commercial plans, building strong sustainable brands, launching new products and leading manufacturing, supply chain and quality operations. Over the past 20 years, he has been focused on the ophthalmic segment, where he has established valuable relationships with key opinion leaders and industry contacts. Prior to joining the Company in 2013, he served as Head of U.S. Marketing and Strategy for ThromboGenics, developing the commercial strategy and building a team to launch a new biologic into the U.S. market, and was Vice President, Business Development at SurModics, working with both large and small pharmaceutical companies on multi-platform drug delivery initiatives. Early on in his career, he held positions of increasing responsibility in both marketing and sales at a number of companies, including his tenure with Bausch & Lomb. Mr. Saharek has a Master of Business Administration from the University of Hartford and a bachelor’s degree from Central Connecticut State University.

Amir H. Shojaei was named Harrow’s Chief Scientific Officer in January 2025, bringing with him nearly 30 years of experience in the life sciences sector. A recognized leader in clinical development, regulatory affairs, and the commercialization of biopharmaceutical and biologic products, Dr. Shojaei oversees Harrow’s medical and clinical affairs, regulatory affairs, pharmacovigilance and QA/compliance for FDA-approved products. Throughout his career, Dr. Shojaei has been instrumental in the advancement of innovative treatments for anterior and posterior segment eye diseases. Notable, he led the development and FDA approval of Xiidra®, a groundbreaking therapy and the first product to treat both the signs and symptoms of dry eye disease. Prior to joining Harrow, he held senior leadership roles at several prominent biopharmaceutical companies, including AsclepiX Therapeutics, TherOptix, Novartis Pharmaceuticals, and Shire Pharmaceuticals (acquired by Takeda). Dr. Shojaei holds a Pharm.D. and Ph.D. from the University of the Pacific. In addition, he is the holder of multiple patents and has authored over 25 peer-reviewed publications.